๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hubei
Clinical trial register · China

Clinical Trials in Hubei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hubei

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT07823829Large B-Cell Lymphoma (LBCL)
UCARsgen Biotech Limited
Phase 1/2
68
Shanghai, Hubei
2026-10-15
Recruiting
Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults
NCT07646600Dilated Cardiomyopathy
AstraZeneca
Observational
10
Beijing, Hubei
2026-08-18
Not yet open
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
NCT07611513Hand, Foot, and Mouth Disease(HFMD), Herpangina
Sinovac Biotech Co., Ltd
Phase 3
6,000
Hefei, Fujian, Henan, Hubei, Sichuan
2026-05
Recruiting
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
NCT07303790Multiple Sclerosis
Daishi Tian
Phase EARLY_PHASE1
9
Hubei
2026-03-09
Recruiting
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
NCT07262333Renal Insufficiency Chronic
Beijing Continent Pharmaceutical Co, Ltd.
Phase 1
56
Hubei
2025-12-25
Not yet open
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Intracerebral Hemorrhage(CBSinICH)
NCT07080632Intracerebral Hemorrhage, Brain Hemorrhage
Tongji Hospital
Not applicable
300
Hubei
2025-10-01
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DualityBio Inc.
Phase 2
450
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
Preliminary Human Trials of F230 Tablets
NCT06899815Pulmonary Hypertension
Beijing Continent Pharmaceutical Co, Ltd.
Phase 1
136
Hubei
2025-05-15
Recruiting
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
NovaOnco Therapeutics Co., Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)
NCT06734832Hand, Foot, and Mouth Disease๏ผˆHFMD)
Sinovac Biotech Co., Ltd
Phase 3
8,000
Hefei, Fujian, Guangdong, Hubei
2024-12-13
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06802666Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Hubei
2024-10-16
Recruiting
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
NCT06542588Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
29
Wuhan, Hubei
2024-07-19
Recruiting
The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
NCT06277791Clinical IVb Stage Oral Squamous Cell Carcinomas Patients
Hospital of Stomatology, Wuhan University
Phase 2
35
Hubei
2023-08-19
Not yet open
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
NCT05909098NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
Xiangyang No.1 People's Hospital
Phase 1/2
33
Hubei
2023-07-01
Recruiting
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
NCT05260385Digestive System Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1/2
133
Beijing, Bengbu, Chongqing, Fujian, Henan, Hubei, Shandong, Shanghai
2022-01-24
By invitation
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
NCT05441475Hepatocellular Carcinoma
Abbisko Therapeutics Co, Ltd
Phase 2
118
Hubei
2021-12-30
Active, closed
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922Ovarian Cancer, Recurrent Cancer
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
NCT05171816Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Active, closed
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
900
Hubei, Hunan, Nanjing
2016-12-22
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hubei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Hubei.

How many clinical trials are recruiting in Hubei?

12 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hubei), 22 studies
PhaseStudiesRecruitingShare
Phase 28436.4%
Phase 35222.7%
Phase 13313.6%
Phase 1/23113.6%
Not applicable104.5%
Observational114.5%
Phase EARLY_PHASE1114.5%

Most active sponsors

Lead sponsors with the most studies (Hubei)
Lead sponsorStudiesRecruiting
Astellas Pharma Global Development, Inc.20
AstraZeneca21
Beijing Continent Pharmaceutical Co, Ltd.22
Sinovac Biotech Co., Ltd21
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology22
Abbisko Therapeutics Co, Ltd10
Beijing Konruns Pharmaceutical Co., Ltd.11
Daiichi Sankyo10
Daishi Tian11
DualityBio Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.